Flegel’s disease is a genodermatosis with manifestation in the second half of life. Topical topical preparations such as those containing urea or cortisone are currently used for therapy. To clarify the genetic cause of this rare dyskeratosis, a research team from Germany and Switzerland conducted a study using next-generation sequencing. The results of the analysis provide valuable insights for the development of new therapeutic approaches.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Stroke
With polypills and co. against stroke and its consequences
- Post-COVID
Complaints from a neurological point of view
- Obstructive sleep apnea syndrome
Fitness to drive with OSAS
- Smoking cessation
On the way to better health – alternative nicotine products in view
- Age-related cognitive impairments
Ginkgo biloba extracts bring benefits
- Casuistry
SLE with kidney damage does not always have to be lupus nephritis
- Viral hepatitis
Hepatitis ABC(EN): Prophylaxis and treatment – an update
- Type 2 diabetes: reduction of microvascular and macrovascular risks